Jinling Pharmaceutical Co., Ltd. (000919) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Jinling Pharmaceutical Co., Ltd.

Why is Jinling Pharmaceutical Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 7.13% and Operating profit at -196.32% over the last 5 years

The company has declared Negative results for the last 4 consecutive quarters

NET PROFIT(HY) At CNY -3.61 MM has Grown at -107.67%
INTEREST(HY) At CNY 3.06 MM has Grown at 2,653.64%
OPERATING CASH FLOW(Y) Lowest at CNY 197.53 MM

With ROE of -0.18%, it has a fair valuation with a 0.91 Price to Book Value

Over the past year, while the stock has generated a return of 6.98%, its profits have fallen by -107.5%
At the current price, the company has a high dividend yield of 1.5

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Jinling Pharmaceutical Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Jinling Pharmaceutical Co., Ltd. for you?

Low Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Jinling Pharmaceutical Co., Ltd.

3.93%

0.53

23.94%

China Shanghai Composite

14.77%

1.01

15.10%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

7.13%

EBIT Growth (5y)

-196.32%

EBIT to Interest (avg)

72.37

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.35

Sales to Capital Employed (avg)

0.84

Tax Ratio

100.00%

Dividend Payout Ratio

146.63%

Pledged Shares

Institutional Holding

ROCE (avg)

4.77%

ROE (avg)

3.84%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.91

EV to EBIT

-9.20

EV to EBITDA

13.19

EV to Capital Employed

0.75

EV to Sales

0.30

PEG Ratio

Dividend Yield

1.46%

ROCE (Latest)

-8.15%

ROE (Latest)

-0.18%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

13What is working for the Company

PRE-TAX PROFIT(Q)

At CNY 29.85 MM has Grown at 476.19%

NET SALES(HY)

At CNY 1,860.65 MM has Grown at 31.18%

NET PROFIT(Q)

At CNY 23.86 MM has Grown at 211.06%

CASH AND EQV(HY)

Highest at CNY 4,162.17 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 11.14%

-24What is not working for the Company

NET PROFIT(HY)

At CNY -3.61 MM has Grown at -107.67%

INTEREST(HY)

At CNY 3.06 MM has Grown at 2,653.64%

OPERATING CASH FLOW(Y)

Lowest at CNY 197.53 MM

ROCE(HY)

Lowest at 0.52%

RAW MATERIAL COST(Y)

Grown by 11.51% (YoY

DEBT-EQUITY RATIO (HY)

Highest at -33.64 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.91%

Here's what is working for Jinling Pharmaceutical Co., Ltd.

Pre-Tax Profit

At CNY 29.85 MM has Grown at 476.19%

over average net sales of the previous four periods of CNY 5.18 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Net Profit

At CNY 23.86 MM has Grown at 211.06%

over average net sales of the previous four periods of CNY 7.67 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CNY MM)

Net Sales

At CNY 1,860.65 MM has Grown at 31.18%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Cash and Eqv

Highest at CNY 4,162.17 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Inventory Turnover Ratio

Highest at 11.14%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Here's what is not working for Jinling Pharmaceutical Co., Ltd.

Interest

At CNY 3.06 MM has Grown at 2,653.64%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Operating Cash Flow

Lowest at CNY 197.53 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Debt-Equity Ratio

Highest at -33.64 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio

Lowest at 2.91%

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost

Grown by 11.51% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales